Show item record

dc.contributor.authorAndré, Claire
dc.contributor.authorMartineau-Dussault, Marie-Ève
dc.contributor.authorBaril, Andrée-Ann
dc.contributor.authorMarchi, Nicola Andrea
dc.contributor.authorDaneault, Véronique
dc.contributor.authorLorrain, Dominique
dc.contributor.authorHudon, Carol
dc.contributor.authorBastien, Célyne
dc.contributor.authorPetit, Dominique
dc.contributor.authorThompson, Cynthia
dc.contributor.authorPoirier, Judes
dc.contributor.authorMontplaisir, Jacques-Yves
dc.contributor.authorGosselin, Nadia
dc.contributor.authorCarrier, Julie
dc.date.accessioned2024-09-10T12:57:19Z
dc.date.availableNO_RESTRICTIONfr
dc.date.available2024-09-10T12:57:19Z
dc.date.issued2024-04-18
dc.identifier.urihttp://hdl.handle.net/1866/33802
dc.publisherOxford University Pressfr
dc.rightsCe document est mis à disposition selon les termes de la Licence Creative Commons Paternité 4.0 International. / This work is licensed under a Creative Commons Attribution 4.0 International License.
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAPOE4fr
dc.subjectREM sleepfr
dc.subjectSleepfr
dc.subjectAgingfr
dc.subjectMild cognitive impairmentfr
dc.subjectPolysomnographyfr
dc.subjectAlzheimer’s diseasefr
dc.subjectDementiafr
dc.titleReduced rapid eye movement sleep in late middle-aged and older apolipoprotein E ɛ4 allele carriersfr
dc.typeArticlefr
dc.contributor.affiliationUniversité de Montréal. Faculté des arts et des sciences. Département de psychologiefr
dc.identifier.doi10.1093/sleep/zsae094
dcterms.abstractStudy Objectives Apolipoprotein E ɛ4 (APOE4) is the strongest genetic risk factor for Alzheimer’s disease (AD). In addition, APOE4 carriers may exhibit sleep disturbances, but conflicting results have been reported, such that there is no clear consensus regarding which aspects of sleep are impacted. Our objective was to compare objective sleep architecture between APOE4 carriers and non-carriers, and to investigate the modulating impact of age, sex, cognitive status, and obstructive sleep apnea (OSA). Methods A total of 198 dementia-free participants aged >55 years old (mean age: 68.7 ± 8.08 years old, 40.91% women, 41 APOE4 carriers) were recruited in this cross-sectional study. They underwent polysomnography, APOE4 genotyping, and a neuropsychological evaluation. ANCOVAs assessed the effect of APOE4 status on sleep architecture, controlling for age, sex, cognitive status, and the apnea–hypopnea index. Interaction terms were added between APOE4 status and covariates. Results Rapid eye movement (REM) sleep percentage (F = 9.95, p = .002, ηp2 = 0.049) and duration (F = 9.23, p = .003, ηp2 = 0.047) were lower in APOE4 carriers. The results were replicated in a subsample of 112 participants without moderate-to-severe OSA. There were no significant interactions between APOE4 status and age, sex, cognitive status, and OSA in the whole sample. Conclusions Our results show that APOE4 carriers exhibit lower REM sleep duration, including in cognitively unimpaired individuals, possibly resulting from early neurodegenerative processes in regions involved in REM sleep generation and maintenance.fr
dcterms.isPartOfurn:ISSN:0161-8105fr
dcterms.isPartOfurn:ISSN:1550-9109fr
dcterms.languageengfr
UdeM.ReferenceFournieParDeposant10.1093/sleep/zsae094fr
UdeM.VersionRioxxVersion publiée / Version of Recordfr
oaire.citationTitleSleepfr
oaire.citationVolume47fr
oaire.citationIssue7fr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show item record

Ce document est mis à disposition selon les termes de la Licence Creative Commons Paternité 4.0 International. / This work is licensed under a Creative Commons Attribution 4.0 International License.
Usage rights : Ce document est mis à disposition selon les termes de la Licence Creative Commons Paternité 4.0 International. / This work is licensed under a Creative Commons Attribution 4.0 International License.